On Oct 09, major Wall Street analysts update their ratings for $MBX Biosciences (MBX.US)$, with price targets ranging from $30 to $44.
J.P. Morgan analyst Jessica Fye initiates coverage with a buy rating, and sets the target price at $30.
Jefferies analyst Michael Yee initiates coverage with a buy rating, and sets the target price at $35.
Guggenheim analyst Seamus Fernandez initiates coverage with a buy rating, and sets the target price at $44.
Stifel analyst Annabel Samimy initiates coverage with a buy rating, and sets the target price at $40.
Furthermore, according to the comprehensive report, the opinions of $MBX Biosciences (MBX.US)$'s main analysts recently are as follows:
MBX Biosciences is advancing its research in the area of peptide-based therapies, focusing on well-established targets within the endocrine/metabolic sector, utilizing its exclusive Precision platform designed to enhance drug profiles. The company's primary candidate, MBX 2109, is seen as a significant initial endeavor into treating chronic hypoparathyroidism, with a Phase II trial currently underway and anticipated results due in the third quarter of 2025. The upcoming year is expected to provide several key milestones and potential value-adding events for MBX's diverse developmental pipeline.
MBX Biosciences is seen to have a promising outlook, with its MBX-2109 treatment in Phase II showing a high likelihood of positive results for parathyroid hormone conditions. The company's robust peptide platform is recognized for its potential to increase the duration and enhance the effectiveness of peptide therapies in the realms of PTH and obesity. Additionally, the current valuation of the company's shares is considered attractive.
The initiation of coverage on MBX Biosciences reflects recognition of its potent and efficient technology platform, which is focused on developing precision endocrine peptides for rare endocrine and metabolic disorders. These disorders present significant market opportunities. MBX Biosciences has fine-tuned pharmaceutical attributes to enhance therapeutic applications—maintaining peptide stability, minimizing variability, prolonging action, and crucially, lessening the necessity for frequent injections.
The potential shown by MBX Biosciences' extended-duration peptides aimed at clinically de-risked targets within specialized endocrine and wider metabolic diseases has been acknowledged. The key focus is on MBX 2109, a pioneering once-weekly peptide that addresses a market opportunity valued at over $7 billion, specifically for post-bariatric hypoglycemia.
Here are the latest investment ratings and price targets for $MBX Biosciences (MBX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月9日，多家華爾街大行更新了$MBX Biosciences (MBX.US)$的評級，目標價介於30美元至44美元。
摩根大通分析師Jessica Fye首次給予買入評級，目標價30美元。
富瑞集團分析師Michael Yee首次給予買入評級，目標價35美元。
Guggenheim分析師Seamus Fernandez首次給予買入評級，目標價44美元。
斯迪富分析師Annabel Samimy首次給予買入評級，目標價40美元。
此外，綜合報道，$MBX Biosciences (MBX.US)$近期主要分析師觀點如下：
MBX生物科學正在推進其在肽類治療領域的研究，專注於內分泌/代謝板塊內的成熟目標，利用其獨家的Precision平台，旨在增強藥物特性。該公司的主力候選藥物MBX 2109被視爲治療慢性甲狀旁腺功能減退症的重要初步嘗試，目前正進行第二階段臨床試驗，預計的結果將於2025年第三季度公佈。未來一年預計將爲MBX多樣化的開發管線提供一些關鍵里程碑和可能增值事件。
MBX生物科學的前景被認爲是光明的，其處於第二階段的MBX-2109治療方案顯示出對甲狀旁腺激素狀況產生積極結果的高概率。該公司強大的肽類平台以其提高肽類療法在PTH和肥胖領域中持續時間和有效性的潛力而聞名。此外，公司股票的當前估值被認爲具有吸引力。
啓動對MBX生物科學的覆蓋反映出對其強大而高效的技術平台的認可，該技術平台專注於爲罕見內分泌和代謝性疾病開發精準內分泌肽。這些疾病提供了重大的市場機會。MBX生物科學已經優化了藥物特性以增強治療應用——保持肽穩定性，減少變異性，延長作用時間，以及至關重要的，減少頻繁注射的需要。
MBX生物科學展示出針對臨床風險較低的專門內分泌和更廣泛代謝疾病的長效肽的潛力得到了認可。重點放在MBX 2109上，這是一種首創的每週一次的肽，針對價值超過70億美元的市場機會，特別是用於術後胃減重術後低血糖症。
以下爲今日4位分析師對$MBX Biosciences (MBX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
